Analyst Names ALLO Stock a CAR-T Leader

ALLO will be in focus tomorrow when the company reports earnings

Nov 4, 2019 at 9:16 AM
facebook X logo linkedin


CAR-T therapy has been the big thing in oncology in recent years, and one name at the forefront of the immuno-oncology movement is Allogene Therapeutics Inc (NASDAQ:ALLO). In fact, Canaccord Genuity came out with a note this morning praising the company, saying its allogeneic CAR-Ts could be a market leader in the allogeneic therapy space, and clinical data should remain strong. Canaccord began coverage on ALLO shares with a "buy" rating and $36 price target.

Looking more broadly, this bull note matches the general sentiment among other brokerage firms in coverage on Allogene Therapeutics. There are already 11 analysts in coverage, and seven of them have "buy" or "strong buy" recommendations. What's more, the average 12-month price target is right where Canaccord is targeting, standing at $37.33.

The stock was last seen trading at $28.94, after going public just over a year ago, when it opened for trading at $22. The shares have bounced around since then in a range of roughly $25 to $33, and right now are trading just atop the newly formed 200-day moving average.

Despite the optimism from analysts, the biotech remains heavily shorted. Short interest accounts for almost 27% of the total float, and represents almost 33 times the average daily trading volume.

The San Francisco-based company should remain in focus, too, since its due to report earnings before the open tomorrow, Nov. 5. Interestingly, the three previous earnings releases have resulted in negative next-day reactions for the stock.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI